Patents by Inventor Russell T. Boggs

Russell T. Boggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6090626
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: July 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Russell T. Boggs
  • Patent number: 6015892
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with a PKC gene or mRNA. Oligonucleotides specifically hybridizable with a particular PKC isozyme, set of isozymes or mRNA transcript are provided. Methods of treating conditions amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with a PKC gene or mRNA are disclosed. Compositions and methods are provided for the treatment, detection and diagnosis of diseases associated with protein kinase C alpha and specific transcripts thereof. New nucleic acid sequences are provided which encode 3' untranslated regions of human protein kinase C alpha polynucleotide probes for PKC alpha are also disclosed.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: January 18, 2000
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Russell T. Boggs, Nicholas M. Dean
  • Patent number: 5952229
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: September 14, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Russell T. Boggs
  • Patent number: 5681747
    Abstract: New nucleic acid sequences are provided which encode 3' untranslated regions of human protein kinase C.alpha.. Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C.alpha.. Oligonucleotides are provided which are specifically hybridizable with nucleic acid encoding PKC.alpha.. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to PKC are disclosed. Polynucleotide probes for PKC.alpha. are also disclosed.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: October 28, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Russell T. Boggs, Nicholas M. Dean
  • Patent number: 5563255
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of detecting the presence of a raf gene using oligonucleotides of the invention, including methods for specific detection of activated truncated raf. Methods of inhibiting hyperproliferation of cells and methods of treating conditions arising from abnormal raf expression which employ oligonucleotides of the invention are also provided.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: October 8, 1996
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Russell T. Boggs